118 related articles for article (PubMed ID: 38330148)
21. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy.
Kanemaru Y; Natsumeda M; Okada M; Saito R; Kobayashi D; Eda T; Watanabe J; Saito S; Tsukamoto Y; Oishi M; Saito H; Nagahashi M; Sasaki T; Hashizume R; Aoyama H; Wakai T; Kakita A; Fujii Y
Acta Neuropathol Commun; 2019 Jul; 7(1):119. PubMed ID: 31345255
[TBL] [Abstract][Full Text] [Related]
22. Novel Targeting of Transcription and Metabolism in Glioblastoma.
Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J
Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993
[No Abstract] [Full Text] [Related]
23. Efficacy of EGFR plus TNF inhibition in a preclinical model of temozolomide-resistant glioblastoma.
Guo G; Gong K; Puliyappadamba VT; Panchani N; Pan E; Mukherjee B; Damanwalla Z; Bharia S; Hatanpaa KJ; Gerber DE; Mickey BE; Patel TR; Sarkaria JN; Zhao D; Burma S; Habib AA
Neuro Oncol; 2019 Dec; 21(12):1529-1539. PubMed ID: 31363754
[TBL] [Abstract][Full Text] [Related]
24. Downregulation of SNRPG induces cell cycle arrest and sensitizes human glioblastoma cells to temozolomide by targeting Myc through a p53-dependent signaling pathway.
Lan Y; Lou J; Hu J; Yu Z; Lyu W; Zhang B
Cancer Biol Med; 2020 Feb; 17(1):112-131. PubMed ID: 32296580
[No Abstract] [Full Text] [Related]
25. Integrative multi-omics characterization reveals sex differences in glioblastoma.
Jang B; Yoon D; Lee JY; Kim J; Hong J; Koo H; Sa JK
Biol Sex Differ; 2024 Mar; 15(1):23. PubMed ID: 38491408
[TBL] [Abstract][Full Text] [Related]
26. PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition.
Gao Z; Xu J; Fan Y; Qi Y; Wang S; Zhao S; Guo X; Xue H; Deng L; Zhao R; Sun C; Zhang P; Li G
J Exp Clin Cancer Res; 2022 Jul; 41(1):223. PubMed ID: 35836243
[TBL] [Abstract][Full Text] [Related]
27. Epithelioid glioblastoma with microglia features: potential for novel therapy.
Nakagomi N; Sakamoto D; Hirose T; Takagi T; Murase M; Nakagomi T; Yoshimura S; Hirota S
Brain Pathol; 2020 Nov; 30(6):1119-1133. PubMed ID: 32687679
[TBL] [Abstract][Full Text] [Related]
28. Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress Glioblastoma Tumor Growth.
Lee J; Shin YJ; Lee K; Cho HJ; Sa JK; Lee SY; Kim SH; Lee J; Yoon Y; Nam DH
Cancer Res Treat; 2018 Jul; 50(3):1009-1022. PubMed ID: 29129044
[TBL] [Abstract][Full Text] [Related]
29. Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Saeed MEM; Kadioglu O; Greten HJ; Yildirim A; Mayr K; Wenz F; Giordano FA; Efferth T
Invest New Drugs; 2021 Jun; 39(3):670-685. PubMed ID: 33313992
[TBL] [Abstract][Full Text] [Related]
30. Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation.
Hou Z; Wu H; Luo N; Li S; Zhang X; Dong S; Zhu D; Zhang H; Tao R
Oncologist; 2023 May; 28(5):449-452. PubMed ID: 36913260
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
[TBL] [Abstract][Full Text] [Related]
32. Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Sharifi Z; Abdulkarim B; Meehan B; Rak J; Daniel P; Schmitt J; Lauzon N; Eppert K; Duncan HM; Petrecca K; Guiot MC; Jean-Claude B; Sabri S
Clin Cancer Res; 2019 Dec; 25(24):7594-7608. PubMed ID: 31540977
[TBL] [Abstract][Full Text] [Related]
33. Cell quiescence correlates with enhanced glioblastoma cell invasion and cytotoxic resistance.
Atkins RJ; Stylli SS; Kurganovs N; Mangiola S; Nowell CJ; Ware TM; Corcoran NM; Brown DV; Kaye AH; Morokoff A; Luwor RB; Hovens CM; Mantamadiotis T
Exp Cell Res; 2019 Jan; 374(2):353-364. PubMed ID: 30562483
[TBL] [Abstract][Full Text] [Related]
34. Lucanthone, a Potential PPT1 Inhibitor, Perturbs Stemness, Reduces Tumor Microtube Formation, and Slows the Growth of Temozolomide-Resistant Gliomas In Vivo.
Radin DP; Shifman S; Outhwaite IR; Sharma A; Bases R; Seeliger MA; Tsirka SE
J Pharmacol Exp Ther; 2024 Mar; 389(1):51-60. PubMed ID: 38296645
[TBL] [Abstract][Full Text] [Related]
35. Proteogenomic and metabolomic characterization of human glioblastoma.
Wang LB; Karpova A; Gritsenko MA; Kyle JE; Cao S; Li Y; Rykunov D; Colaprico A; Rothstein JH; Hong R; Stathias V; Cornwell M; Petralia F; Wu Y; Reva B; Krug K; Pugliese P; Kawaler E; Olsen LK; Liang WW; Song X; Dou Y; Wendl MC; Caravan W; Liu W; Cui Zhou D; Ji J; Tsai CF; Petyuk VA; Moon J; Ma W; Chu RK; Weitz KK; Moore RJ; Monroe ME; Zhao R; Yang X; Yoo S; Krek A; Demopoulos A; Zhu H; Wyczalkowski MA; McMichael JF; Henderson BL; Lindgren CM; Boekweg H; Lu S; Baral J; Yao L; Stratton KG; Bramer LM; Zink E; Couvillion SP; Bloodsworth KJ; Satpathy S; Sieh W; Boca SM; Schürer S; Chen F; Wiznerowicz M; Ketchum KA; Boja ES; Kinsinger CR; Robles AI; Hiltke T; Thiagarajan M; Nesvizhskii AI; Zhang B; Mani DR; Ceccarelli M; Chen XS; Cottingham SL; Li QK; Kim AH; Fenyö D; Ruggles KV; Rodriguez H; Mesri M; Payne SH; Resnick AC; Wang P; Smith RD; Iavarone A; Chheda MG; Barnholtz-Sloan JS; Rodland KD; Liu T; Ding L;
Cancer Cell; 2021 Apr; 39(4):509-528.e20. PubMed ID: 33577785
[TBL] [Abstract][Full Text] [Related]
36. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
[TBL] [Abstract][Full Text] [Related]
37. Differential expression of MicroRNAs in patients with glioblastoma after concomitant chemoradiotherapy.
Park EC; Kim G; Jung J; Wang K; Lee S; Jeon SS; Lee ZW; Kim SI; Kim S; Oh YT; Shin JH; Jang HS; Choi BO; Kim GH
OMICS; 2013 May; 17(5):259-68. PubMed ID: 23586679
[TBL] [Abstract][Full Text] [Related]
38. Smoothened Promotes Glioblastoma Radiation Resistance Via Activating USP3-Mediated Claspin Deubiquitination.
Tu Y; Chen Z; Zhao P; Sun G; Bao Z; Chao H; Fan L; Li C; You Y; Qu Y; Chen Y; Ji J
Clin Cancer Res; 2020 Apr; 26(7):1749-1762. PubMed ID: 31900278
[TBL] [Abstract][Full Text] [Related]
39. Albumin-bound paclitaxel augment temozolomide treatment sensitivity of glioblastoma cells by disrupting DNA damage repair and promoting ferroptosis.
Qu S; Qi S; Zhang H; Li Z; Wang K; Zhu T; Ye R; Zhang W; Huang G; Yi GZ
J Exp Clin Cancer Res; 2023 Oct; 42(1):285. PubMed ID: 37891669
[TBL] [Abstract][Full Text] [Related]
40. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation.
Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK
Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
